CD79A and inflammatory bowel disease: In contrast, IgG in the lumen has been shown to be elevated in IBD patients [32–34] and IgG+ intestinal plasmablasts are greater than 3-fold more reactive to specific pathobionts than IgA+ plasmablasts [35, 36], demonstrating IgG’s pathogen-binding specificity.